---
aliases: [MRK, Merck & Co]
---
#actor #pharma #oncology #usa #public

**Merck** — Keytruda dominance. $25B+ cancer drug. Patent cliff 2028. Vaccines (Gardasil).

---

## Why Merck matters

| Metric | Value |
|--------|-------|
| Ticker | MRK (NYSE) |
| Keytruda revenue | **$25B+** annually |
| Patent expiry | **2028** (US) |
| Market cap | ~$250B |

---

## Keytruda franchise

| Metric | Value |
|--------|-------|
| Revenue | $25B+ (2024) |
| Indications | 40+ cancer types |
| Market position | #1 cancer drug globally |
| Patent expiry | 2028 (US) |

**The cliff:** Keytruda is ~40% of Merck revenue. 2028 expiry is existential.

---

## Other key products

| Product | Category | Revenue |
|---------|----------|---------|
| **Gardasil** | HPV vaccine | $8B+ |
| Lagevrio | COVID antiviral | Declining |
| Animal Health | Veterinary | $6B+ |
| Januvia/Janumet | Diabetes | LOE pressure |

---

## Patent cliff strategy

| Approach | Detail |
|----------|--------|
| Subcutaneous Keytruda | New formulation for extended exclusivity |
| Label expansion | More indications |
| Combinations | ADCs, other modalities |
| M&A | Pipeline acquisition |

---

## Pipeline

| Asset | Indication | Status |
|-------|------------|--------|
| MK-2870 | ADC (HER2) | Phase 3 |
| V116 | Pneumococcal vaccine | FDA approved |
| Sotatercept | PAH | Approved |

---

## Recent M&A

| Target | Value | Rationale |
|--------|-------|-----------|
| Prometheus | $10.8B | Immunology |
| Acceleron | $11.5B | Sotatercept |

**Strategy:** Diversify beyond Keytruda.

---

## Investment case

**Bull:**
- Keytruda peak not reached
- Gardasil growth runway
- M&A filling pipeline
- Strong cash flow for deals

**Bear:**
- 2028 patent cliff looming
- 40% revenue concentration
- Biosimilar competition coming
- M&A execution risk

---

## TCJA repatriation (2018)

Merck repatriated significant overseas cash under the [[Tax Cuts and Jobs Act]] one-time tax holiday. Deployed into M&A to address Keytruda patent cliff.

---

## Quick stats

| Metric | Value |
|--------|-------|
| Ticker | MRK |
| Exchange | NYSE |
| Revenue | ~$60B |
| Focus | Oncology, vaccines |

---

## Potential M&A: Revolution Medicines (Jan 2026)

| Detail | Value |
|--------|-------|
| Target | Revolution Medicines |
| Reported value | **$32B** |
| Status | In talks |
| Product | Late-stage oral cancer treatment |
| Context | Biggest biotech deal since Pfizer-Seagen ($43B, 2023) |

**CEO Mark Davis:** Sees opportunity for deals worth "multi tens of billions" — "We are not limited from a balance sheet."

---

## Related

- [[Biopharma]] — sector
- [[Pfizer]] — pharma peer
- [[Tax Cuts and Jobs Act]] — repatriation (2018)

---

## Sources

- [Merck investor relations](https://www.merck.com/investor-relations/)

*Updated 2026-01-17*
